GRI Bio, Inc.
GRI Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.45
KIRA · Stoqly’s AI analyst, in plain words
- GRI Bio, Inc. lost $12.0M in fiscal 2025.
- Free cash flow was −$10.2M in fiscal 2025, — of revenue.
Market cap
$2.6M
P/E
0.0x
Revenue
—
Net income
−$12.0M
Free cash flow
−$10.2M
Operating margin
—
GRI Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$12.0M
No. It lost money last year.
How is the share priced?
0.0x
One share costs 0.0 times its yearly profit per share.
What GRI Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Jan 30, 2026
- Legal name
- GRI Bio, Inc.
- CIK
- 0001824293
GRI Bio, Inc. · GRI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | — | — | — | — |
| Revenue growth | −100.0% | — | — | — | — |
| Net income | −$9.3M | −$3.2M | −$13.0M | −$8.2M | −$12.0M |
| Diluted EPS | −$1.42 | −$24.95 | −$5,018.09 | −$1,545.55 | −$121.80 |
| Cash | |||||
| Cash from operations | −$8.3M | −$1.1M | −$9.0M | −$8.6M | −$10.2M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$8.3M | −$1.1M | −$9.0M | −$8.6M | −$10.2M |
| Share count change | 45.2% | −98.0% | −98.0% | 150.0% | 1,410.8% |
| Debt and strength | |||||
| Cash and short-term investments | $7.5M | $0.0M | $1.8M | $5.0M | $8.2M |
| Shareholders' equity | −$4.8M | −$1.6M | $0.3M | $4.0M | $6.0M |
| Current ratio | 3.3x | 0.2x | 1.1x | 3.4x | 3.3x |
| Returns and quality | |||||
| Return on equity | — | — | — | −382.5% | −238.2% |
| Return on tangible equity | — | — | −5,033.6% | −250.9% | −199.0% |
| Piotroski F-score | 3 | — | — | — | — |
| Altman Z'' | −13.6 | −226.4 | −60.0 | −25.2 | −21.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GRI Bio, Inc. · GRI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.45 a share, the company is worth $2.6M: 0.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001824293). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.